In this episode, David Drapkin interviews Dr. Ben Medrano: Co-Medical Director with Nue Life, board-certified psychiatrist specializing in integrative psychiatry, and former Senior Vice President and US Medical Director of Field Trip Health.

Medrano discusses stigmatization (of some modalities like electro-shock treatment, of psychedelics, and of ketamine – which seems to be stigmatized even within the psychedelic space); his concerns that the at-home ketamine model is at risk as we make our way out of the pandemic; and how at-home ketamine can drastically reduce the cost of treatment. And he discusses some Nue Life highlights: their just-released 664 participant-study in Frontiers Psychiatry showing the safety of at-home ketamine; Nue Care, their model for aftercare using digital phenotyping, goals, and a scoring system; and their Nue Network, which could be a solution for better education on ketamine and for granting access for patients through prescribers who typically don't understand much about its efficacy.

For more, head to:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]

свернуть